Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Shares Acquired by Andra AP fonden

Share on StockTwits

Andra AP fonden increased its position in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 24.0% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 27,900 shares of the biopharmaceutical company’s stock after acquiring an additional 5,400 shares during the period. Andra AP fonden’s holdings in Alexion Pharmaceuticals were worth $2,733,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Steward Partners Investment Advisory LLC acquired a new stake in shares of Alexion Pharmaceuticals in the 2nd quarter worth about $28,000. Redhawk Wealth Advisors Inc. acquired a new stake in shares of Alexion Pharmaceuticals in the 2nd quarter worth about $29,000. Ossiam acquired a new stake in shares of Alexion Pharmaceuticals in the 2nd quarter worth about $32,000. Capital Bank & Trust Co increased its holdings in shares of Alexion Pharmaceuticals by 355.9% in the 2nd quarter. Capital Bank & Trust Co now owns 269 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 210 shares during the period. Finally, NEXT Financial Group Inc acquired a new stake in shares of Alexion Pharmaceuticals in the 2nd quarter worth about $36,000. 91.60% of the stock is currently owned by institutional investors and hedge funds.

Alexion Pharmaceuticals stock opened at $112.91 on Tuesday. The stock has a market cap of $25.21 billion, a price-to-earnings ratio of 12.45, a PEG ratio of 1.08 and a beta of 1.67. The company has a current ratio of 3.98, a quick ratio of 3.45 and a debt-to-equity ratio of 0.25. The company’s 50-day moving average price is $107.60 and its two-hundred day moving average price is $113.17. Alexion Pharmaceuticals, Inc. has a 52 week low of $92.56 and a 52 week high of $141.86.

Alexion Pharmaceuticals (NASDAQ:ALXN) last released its earnings results on Wednesday, October 23rd. The biopharmaceutical company reported $2.79 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.47 by $0.32. The firm had revenue of $1.26 billion for the quarter, compared to analysts’ expectations of $1.24 billion. Alexion Pharmaceuticals had a net margin of 31.05% and a return on equity of 21.21%. Alexion Pharmaceuticals’s quarterly revenue was up 23.0% on a year-over-year basis. During the same quarter last year, the company earned $2.02 EPS. Research analysts expect that Alexion Pharmaceuticals, Inc. will post 9.43 earnings per share for the current fiscal year.

A number of analysts recently weighed in on the stock. Evercore ISI reaffirmed a “buy” rating and issued a $145.00 price objective on shares of Alexion Pharmaceuticals in a report on Sunday, November 17th. Stifel Nicolaus reaffirmed a “hold” rating on shares of Alexion Pharmaceuticals in a report on Friday, August 30th. Robert W. Baird set a $165.00 price objective on shares of Alexion Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, August 30th. SunTrust Banks assumed coverage on shares of Alexion Pharmaceuticals in a report on Tuesday, November 12th. They issued a “buy” rating and a $125.00 price objective on the stock. Finally, Bank of America assumed coverage on shares of Alexion Pharmaceuticals in a report on Thursday, October 17th. They issued a “buy” rating on the stock. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and sixteen have given a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $156.37.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.

Featured Story: Forex

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.